Literature DB >> 18509183

High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma.

Xiao-Dong Zhu1, Ju-Bo Zhang, Peng-Yuan Zhuang, Hong-Guang Zhu, Wei Zhang, Yu-Quan Xiong, Wei-Zhong Wu, Lu Wang, Zhao-You Tang, Hui-Chuan Sun.   

Abstract

PURPOSE: To investigate prognostic values of the intratumoral and peritumoral expression of macrophage colony-stimulating factors (M-CSF) in hepatocellular carcinoma (HCC) patients after curative resection. PATIENTS AND METHODS: Expression of M-CSF and density of macrophages (M Phi) were assessed by immunohistochemistry in tissue microarrays containing paired tumor and peritumoral liver tissue from 105 patients who had undergone hepatectomy for histologically proven HCC. Prognostic value of these and other clinicopathologic factors was evaluated.
RESULTS: Neither intratumoral M-CSF nor M Phi density was associated with overall survival (OS) or disease-free survival (DFS). High peritumoral M-CSF and M Phi density, which correlated with large tumor size, presence of intrahepatic metastasis, and high TNM stage, were independent prognostic factors for both OS (P = .001 and P < .001, respectively) and DFS (P = .001 and P = .003, respectively) and affected incidence of early recurrence. In a small HCC subset, peritumoral M-CSF was also correlated with both OS and DFS (P = .038 and P = .001, respectively). The combination of peritumoral M-CSF and M Phi had a better power to predict the patients' death and disease recurrence (P < .001 for both).
CONCLUSION: High peritumoral M-CSF and M Phi were associated with HCC progression, disease recurrence, and poor survival after hepatectomy, highlighting the importance of peritumoral tissue in the recurrence and metastasis of HCC. M-CSF and M Phi may be targets of postoperative adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509183     DOI: 10.1200/JCO.2007.15.6521

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  247 in total

Review 1.  Macrophage diversity enhances tumor progression and metastasis.

Authors:  Bin-Zhi Qian; Jeffrey W Pollard
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

2.  Prognostic value of purinergic P2X7 receptor expression in patients with hepatocellular carcinoma after curative resection.

Authors:  Haiou Liu; Weisi Liu; Zheng Liu; Yidong Liu; Weijuan Zhang; Le Xu; Jiejie Xu
Journal:  Tumour Biol       Date:  2015-02-27

3.  Microlocalization of CD68+ tumor-associated macrophages in tumor stroma correlated with poor clinical outcomes in oral squamous cell carcinoma patients.

Authors:  Yan-Hong Ni; Liang Ding; Xiao-Feng Huang; Ying-chun Dong; Qin-Gang Hu; Ya-Yi Hou
Journal:  Tumour Biol       Date:  2015-02-11

4.  Can combination of osteopontin and peritumor-infiltrating macrophages be a prognostic marker of early-stage hepatocellular carcinoma?

Authors:  Yoo Jin Lee; Byoung Kuk Jang
Journal:  Hepatobiliary Surg Nutr       Date:  2014-04       Impact factor: 7.293

5.  Importance of tumor/stroma interactions in prognosis of hepatocellular carcinoma.

Authors:  Noemí Eiró; Francisco J Vizoso
Journal:  Hepatobiliary Surg Nutr       Date:  2014-04       Impact factor: 7.293

Review 6.  Myeloid cells in hepatocellular carcinoma.

Authors:  Shanshan Wan; Ning Kuo; Ilona Kryczek; Weiping Zou; Theodore H Welling
Journal:  Hepatology       Date:  2015-07-01       Impact factor: 17.425

7.  Accomplishments in 2008 in the management of hepatobiliary cancers.

Authors:  Andrew X Zhu; Anthony El-Khoueiry; Josep M Llovet
Journal:  Gastrointest Cancer Res       Date:  2009-09

Review 8.  Tumor-associated macrophages and anti-tumor therapies: complex links.

Authors:  Cristina Belgiovine; Maurizio D'Incalci; Paola Allavena; Roberta Frapolli
Journal:  Cell Mol Life Sci       Date:  2016-03-08       Impact factor: 9.261

9.  Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.

Authors:  Rikke B Holmgaard; Alexandra Brachfeld; Billel Gasmi; David R Jones; Marissa Mattar; Thompson Doman; Mary Murphy; David Schaer; Jedd D Wolchok; Taha Merghoub
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

10.  Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.

Authors:  Zhiyuan Lin; Li Liu; Yu Xia; Xiang Chen; Ying Xiong; Yang Qu; Jiajun Wang; Qi Bai; Jianming Guo; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.